Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Tristel’s Revenue Growth and Higher Final Dividend Put Infection-Control Demand in Focus

- Investors should distinguish confirmed information from expectations, proposals and early-stage indicators.

Ankur Sharma | 20 October 2026

GSK Lung-Cancer Data Draws Attention to Ris-Rez Combination and Clinical Milestones

- Investors should distinguish confirmed information from expectations, proposals and early-stage indicators.

Ankur Sharma | 20 October 2026

Hemogenyx Feasibility Study Agreement Puts Development Strategy Under Review

- Hemogenyx Pharmaceuticals PLC is in focus following a company update published or highlighted on 19 October 2026.

Ankur Sharma | 20 October 2026

Faron’s MATINS Survival Update Brings Bexmarilimab Back Into Focus (LSE:FARN)

Faron announced that complete survival data for 25 patients in the melanoma cohort of MATINS will be presented at the October 2026 oncology congress. The patients had metastatic melanoma that had progressed despite checkpoint-inhibitor treatment, making the population clinically challenging and heavily pretreated.

Ankur Sharma | 20 October 2026

Nuformix Reports Fresh Biological Evidence for Its Inhaled Fibrosis Candidate (LSE:NFX)

Nuformix reported further positive target-engagement results from its pilot inhaled study of NXP002, a drug-repurposing programme being developed for idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and related interstitial lung diseases. The company said testing showed statistically significant modulation of TGF-β/SMAD signalling, a pathway involved …

Ankur Sharma | 20 October 2026

PureTech Health’s LYT-200 Cancer Data Set for a Major October Spotlight (LSE:PRTC)

PureTech Health announced that Phase 1b results for LYT-200, developed by its founded entity Gallop Oncology, have been accepted for an oral presentation at the October 2026 oncology congress. The data concern relapsed or refractory high-risk myelodysplastic syndromes and acute myeloid leukaemia, patient groups …

Ankur Sharma | 20 October 2026

FTSE 100 GSK (LSE:GSK) Ticks Higher as Ris-Rez Hits 61% Response Rate in First Global Lung Cancer Data

GSK plc (LSE:GSK) is one of the FTSE 100 stocks in focus on Monday, 19 October 2026, after the drugmaker presented the first global data for its experimental lung cancer treatment risvutatug rezetecan, known as Ris-Rez. Shares were marginally higher at about 1,863p in …

Ankur Sharma | 20 October 2026

FTSE 100 Haleon (LSE:HLN) Draws Defensive Flows Near 375p as Oral Health Momentum Builds Into Q3 Update

Haleon PLC (LSE:HLN) is in focus on Monday, 19 October 2026, as investors look for steady earners amid a volatile market. The consumer health group behind Sensodyne, Panadol, Advil and Centrum traded around 375p after a period in which healthcare and consumer staples shares …

Ankur Sharma | 20 October 2026

FTSE 100 Smith & Nephew (LSE:SN.) Near Yearly Low as CARTIHEAL Launch and Q3 Report Set Up Key November Test

Smith & Nephew plc (LSE:SN.) is in focus on Monday, 19 October 2026, as the medical technology group trades close to its lowest levels of the year. The maker of orthopaedic implants, sports medicine products and advanced wound care treatments has struggled with slower …

Ankur Sharma | 20 October 2026

Oxford Nanopore Shares Extend Stunning Comeback as FTSE 250 Gene Sequencing Star Shines (LSE:ONT)

The latest move adds to an extraordinary turnaround. In July, Oxford Nanopore shares plunged around 11% to 106.5p after the company warned that revenue for the six months to 30 June would come in at about £116.5 million, below market expectations, mainly because of …

Ankur Sharma | 20 October 2026
Support

Hi! How can we help you today?

Loading…